<DOC>
	<DOCNO>NCT02370680</DOCNO>
	<brief_summary>This study conduct evaluate safety length effect platelet build-up artery Durlaza™ compare immediate-release Bayer® aspirin 81 mg subject 's current aspirin 81 mg choice patient Type 2 diabetes mellitus cardiovascular disease multiple risk factor develop cardiovascular disease .</brief_summary>
	<brief_title>Length Effect Extended Release Aspirin Platelets Patients With Diabetes Heart Disease</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>Male nonlactating , nonpregnant female subject A history Type 2 Diabetes history least one following : Coronary Artery Disease , Peripheral Vascular Disease , Ischemic Stroke , along least 2 CVD risk factor ( obese , smoker , ≥ 55 year age , prior thrombotic event ) Sensitivity aspirin NSAID ( nonsteroidal antiinflammatory drug ) , Evidence uncontrolled unstable cardio cerebrovascular disorder , Presence uncontrolled chronic medical illness , GI disorder surgery lead impaired drug absorption , clinically significant abnormal baseline ECG , history hepatitis , malignancy within past five year , HIV , history alcohol drug abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Antiplatelet</keyword>
	<keyword>Antiplatelet therapy</keyword>
	<keyword>platelet turnover</keyword>
	<keyword>high platelet turnover</keyword>
	<keyword>platelet aggregation</keyword>
	<keyword>cardiovascular disease</keyword>
	<keyword>coronary artery disease</keyword>
	<keyword>diabetes mellitus</keyword>
</DOC>